In Brief: Summit Technology/Visx
This article was originally published in The Gray Sheet
Summit Technology/Visx: Ophthalmic laser firms reach settlement of "all outstanding U.S. and international patent infringement disputes between them, including the infringement litigation in Delaware related to Summit's Azema patent and in Canada related to Visx's L'Esperance patents," the firms state. Under the terms of the agreement, the companies cross-license each other's foreign patents; in the U.S., Summit's Azema patent is contributed to Pillar Point Partners, a joint venture formed in 1992 to hold U.S. eye laser patents. An exchange of payments under the pact will result in a net $4.5 mil. payment to Summit...
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.